Form 4: Viracta Therapeutics Director Ivor Royston Reports Stock Transactions

Director Ivor Royston of Viracta Therapeutics reports the acquisition and disposal of common stock and vesting of restricted stock units.

Summary

• On May 25, 2024, Ivor Royston, a director of Viracta Therapeutics, Inc. (VIRX), reported transactions involving the company's stock.
• Royston acquired 25,219 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• Concurrently, Royston disposed of 25,219 shares of common stock.
• Following these transactions, Royston directly owns 100,876 shares and indirectly owns 18,599 shares through a spouse.
• The RSUs vest quarterly, with one-eighth vesting on November 25, 2021, and one-sixteenth vesting each quarter thereafter, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with neutral sentiment.

Positives

• The vesting of RSUs indicates a continued alignment of the director's interests with the company's performance.

Future Outlook

The director's holdings will continue to change as RSUs vest quarterly, contingent upon continued service.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions, allowing investors to track the buying and selling activity of company insiders.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's stock.

Key Dates

Keywords

Form 4, Viracta Therapeutics, VIRX, Ivor Royston, Director, Stock Transaction, Restricted Stock Units, RSU, Beneficial Ownership, Securities Exchange Act